欧美在线导航,丰满熟妇人妻中文字幕

首頁(yè)> 產(chǎn)品列表> 先導(dǎo)化合物三唑并[n，m-a]吡啶和嘧啶>

Tofimilast

NMR下載 COA and HPLC MSDS下載
names：
9-Cyclopentyl-7-ethyl-3-(thiophen-2-yl)-6,9-dihydro-5H-pyrazolo(3,4-c)-1,2,4-triazolo(4,3-a)pyridine
CAS號(hào)：
185954-27-2
MDL Number：
MF(分子式)： C18H21N5S MW(分子量)： 339.461
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價(jià)格 (￥)	現(xiàn)價(jià)(￥)	特價(jià)(￥)	庫(kù)存描述	數(shù)量	總計(jì) (￥)

大包裝詢價(jià) 提供各種包裝，敬請(qǐng)垂詢
收藏商品商品點(diǎn)評(píng) 加入購(gòu)物車立即購(gòu)買

快速詢價(jià)

收起

你想詢價(jià)的產(chǎn)品

*產(chǎn)品名稱：

CAS號(hào)：

產(chǎn)品編號(hào)：

需求描述：

請(qǐng)準(zhǔn)確填寫(xiě)您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗(yàn)證碼：

詢價(jià)

中文別名	9-Cyclopentyl-7-ethyl-3-(thiophen-2-yl)-6,9-dihydro-5H-pyrazolo(3,4-c)-1,2,4-triazolo(4,3-a)pyridine
英文別名	Tofimilast; CP-325366; CP 325366; CP325366; CP-325,366; CP 325,366; CP325,366.
CAS號(hào)	185954-27-2
Inchi	InChI=1S/C18H21N5S/c1-2-14-13-9-10-22-17(15-8-5-11-24-15)19-20-18(22)16(13)23(21-14)12-6-3-4-7-12/h5,8,11-12H,2-4,6-7,9-10H2,1H3
InchiKey	DHCOPPHTVOXDKU-UHFFFAOYSA-N
分子式 Formula	C18H21N5S
分子量 Molecular Weight	339.461
溶解度Solubility
性狀	Solid powder
儲(chǔ)藏條件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

產(chǎn)品說(shuō)明	Tofimilast(CAS:185954-27-2):僅限應(yīng)用于工業(yè)或者科學(xué)研究過(guò)程中非醫(yī)療目的，不應(yīng)用于人類或動(dòng)物的臨床診斷以及治過(guò)程療，該產(chǎn)品非藥用，非食用。
Introduction	Tofimilast, also known as CP-325366, is a PDE4 inhibitor potentially for the treatment of asthma and chronic obstructive pulmonary disease.
Application1
Application2
Application3

警示圖
危險(xiǎn)性	Warning
危險(xiǎn)性警示
安全聲明
安全防護(hù)
備注

[1]Jaffari S, Forbes B, Collins E, Barlow DJ, Martin GP, Murnane D. Rapidcharacterisation of the inherent dispersibility of respirable powders using drydispersion laser diffraction. Int J Pharm. 2013 Apr 15;447(1-2):124-3[1]doi:10.1016/j.ijpharm.2013.02.034. PubMed PMID: 23434542; PubMed Central PMCID:PMC3636537.

[2]Tralau-Stewart CJ, Williamson RA, Nials AT, Gascoigne M, Dawson J, Hart GJ,Angell AD, Solanke YE, Lucas FS, Wiseman J, Ward P, Ranshaw LE, Knowles RG.GSK256066, an exceptionally high-affinity and selective inhibitor ofphosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic,and in vivo characterization. J Pharmacol Exp Ther. 2011 Apr;337(1):145-54. doi:10.1124/jpet.110.173690. PubMed PMID: 21205923.

[3] Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors berealized: guarded optimism or wishful thinking? Br J Pharmacol. 2008Oct;155(3):288-90. doi: 10.1038/bjp.2008.297. PubMed PMID: 18660832; PubMedCentral PMCID: PMC2567889.

[4] Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find ExpClin Pharmacol. 2007 Sep;29(7):467-509. PubMed PMID: 17982511.

[5] Duplantier AJ, Bachert EL, Cheng JB, Cohan VL, Jenkinson TH, Kraus KG,McKechney MW, Pillar JD, Watson JW. SAR of a series of5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potentinhibitors of human eosinophil phosphodiesterase. J Med Chem. 2007 Jan25;50(2):344-9. PubMed PMID: 17228876.

對(duì)不起，暫無(wú)產(chǎn)品評(píng)價(jià)！

MSDS

SDS 1.0 中文

展開(kāi)

SDS 1.0 英文

展開(kāi)